Saturday, December 02, 2017 5:12:48 PM
total nonsense, ever hear of embeda, ever look at the patents that many others had, most notably Oshlack? remember, elite had to squeak around Oshlack's patents to even get issued. Oh, and by the way this ahead of its time technology seems to be a bit problematic (hi Tmax). I prefer my history to be factually correct
Whoa, doc, hold on. I'm not meaning to overstate. I never said it was revolutionary, I said it was before its time. It's a clever tweak of the antagonist concept, just unique enough to qualify for a patent and give a pathway to commercialization. The patent has not been challenged, so who knows how squeaky it really is. But what I was trying to express is that Elite started an ADF company multiple years before OxyContin came out. It would be nine more years until the movie OxyContin Express won the Peabody for documenting the craziness in Florida. By then, Elite had been less than a dime for nearly two years. ADF OxyContin didn't come out until 2010, and before that nobody ever heard of an ADF label. A lot has changed since then. We have a whole new language for describing ADF properties, testing for effectiveness, and certifying the label. My bet here is that it is worth something to have a unique ADF tech that can readily meet the requirements for chewing, snorting, and IV abuse deterrence labels for any opioid agonist and any time-release characteristic (even if it isn't first and isn't revolutionary). I own about one in 500 share of this very cool, very versatile ADF tech, and I'm very much looking forward to seeing how it turns out. Patience, my friend.
P.S. The tmax problem you mention is another one of those unforced errors I like to talk about. Nonetheless, the tmax thing is an issue with the agonist bead, specifically the oxycodone IR bead. It wouldn't be expected to have any effect on the antagonist bead or apply to any other agonist bead. It has nothing to do with Elite's ADF tech.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136591415
But the antagonist ADF tech the company was originally based on was way before its time. Even now, with the opioid epidemic in full bloom, we still allow kids to snort non-ADF IR opioids like oxyIR, Norco, and Percocet. It never had a chance in the early 2000's, which was years before anybody ever heard of OxyContin, Hillbilly heroin, or pill mills. If ever there was a time to commercialize the original ADF tech, now is it. Elite has ready-to-go antagonist ADF versions of Norco and Percocet, and as always, the ADF oxyIR version should be ready to go soon. Maybe someday somebody will decide we ought not to let kids snort this crap. After all these years, Elite is ready for that day to be today.
Call on God but row away from the rocks.
-Hunter S. Thompson
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
